By Helena Smolak
Valneva expects further sales growth this year after it posted higher revenue in 2024.
The French vaccine company said Tuesday that it expects total revenue in 2025 to grow to between 180 million euros and 190 million euros ($188.7 million and $199.2 million) with a positive cashflow. It expects to reach R&D investments of between 90 million and 100 million euros for this year.
Its full-year revenue rose 10% to 169.6 million euros despite lower-than anticipated sales of its attenuated chikungunya vaccine in the U.S.
Its cash and cash equivalents stood at 168.3 million euros as of Dec. 31.
The company will publish its audited full-year results on Mar. 20.
Write to Helena Smolak at helena.smolak@wsj.com
(END) Dow Jones Newswires
February 18, 2025 03:13 ET (08:13 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。